Molecular alterations in precancerous lesions of esophageal squamous cell carcinoma

doi:10.3760/cma.j.issn.1673-422X.2019.07.009

Abstract

Abstract: Esophageal squamous cell carcinoma (ESCC) is one of the most predominant malignancies worldwide. ESCC develops gradually from the precancerous lesions. The researches about biomarkers mainly concentrate in the nucleic acid and protein, including cytogenetic abnormalities, amplifications, deletions, mutations, breakage and fusions of genomic DNA, expression changes of mRNA, microRNA (miRNA) and long noncoding RNA (lncRNA) in RNA level, and expression level, subcellular localization, and posttranslational modifications of proteins. Studies on the molecular alterations in precancerous lesions and early cancer of t he esophagus will contribute to the exploration of biomarkers for early diagnosis and intervention targets for this disease.

Key words: Esophageal neoplasms, Neoplasms, squamous cell, DNA, RNA, Proteins, Precancerous lesions

Chang Chen, Wang Mingrong. Molecular alterations in precancerous lesions of esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2019, 46(7): 430-433.

References

［1］ Smyth EC, Lagergren J, Fitzgerald RC, et al. Oesophageal cancer［J］. Nat Rev Dis Primers, 2017, 3: 17048. DOI: 10.1038/nrdp.2017.48. ［2］郑荣寿, 孙可欣, 张思维, 等. 2015年中国恶性肿瘤流行情况分析［J］.中华肿瘤杂志, 2019, 41(1): 1928. DOI: 10.3760/cma.j.issn.02533766.2019.01.005. ［3］ Wei WQ, Chen ZF, He YT, et al. Longterm followup of a community assignment, onetime endoscopic screening study of esophageal cancer in China［J］. J Clin Oncol, 2015, 33(17): 19511957. DOI: 10.1200/JCO.2014.58.0423. ［4］ Singhi AD, Arnold CA, LamHimlin DM, et al. Targeted nextgeneration sequencing supports epidermoid metaplasia of the esophagus as a precursor to esophageal squamous neoplasia［J］. Mod Pathol, 2017, 30(11): 16131621. DOI: 10.1038/modpathol.2017.73. ［5］ Liu X, Zhang M, Ying S, et al. Genetic alterations in esophageal tissues from squamous dysplasia to carcinoma［J］. Gastroenterology, 2017, 153(1): 166177. DOI: 10.1053/j.gastro.2017.03.033. ［6］ Chen XX, Zhong Q, Liu Y, et al. Genomic comparison of esophageal squamous cell carcinoma and its precursor lesions by multiregion wholeexome sequencing［J］. Nat Commun, 2017, 8(1): 524. DOI: 10.1038/s41467017006500. ［7］ Shi ZZ, Shang L, Jiang YY, et al. Consistent and differential genetic aberrations between esophageal dysplasia and squamous cell carcinoma detected by array comparative genomic hybridization［J］. Clin Cancer Res, 2013, 19(21): 58675878. DOI: 10.1158/10780432.CCR123753. ［8］ Yang YF, Li H, Xu XQ, et al. An expression of squamous cell carcinoma antigen 2 in peripheral blood within the different stages of esophageal carcinogenesis［J］. Dis Esophagus, 2008, 21(5): 395401. DOI: 10.1111/j.14422050.2007.00789.x. ［9］ Hu HB, Jie HY, Zheng XX. Three circulating lncRNA predict early progress of esophageal squamous cell carcinoma［J］. Cell Physiol Biochem, 2016, 40(12): 117125. DOI: 10.1159/000452529. ［10］ Liu Z, Yang T, Xu Z, et al. Upregulation of the long noncoding RNA BANCR correlates with tumor progression and poor prognosis in esophageal squamous cell carcinoma［J］. Biomed Pharmacother, 2016, 82: 406412. DOI: 10.1016/j.biopha.2016.05.014. ［11］ Cui XB, Zhang SM, Xu YX, et al. PFN2, a novel marker of unfavorable prognosis, is a potential therapeutic target involved in esophageal squamous cell carcinoma［J］. J Transl Med, 2016, 14(1): 137. DOI: 10.1186/s129670160884y. ［12］ Choy B, LaLonde A, Que J, et al. MCM4 and MCM7, potential novel proliferation markers, significantly correlated with Ki67, Bmi1, and cyclin E expression in esophageal adenocarcinoma, squamous cell carcinoma, and precancerous lesions［J］. Hum Pathol, 2016, 57: 126135. DOI: 10.1016/j.humpath.2016.07.013. ［13］ Peng J, Hu Q, Liu W, et al. USP9X expression correlates with tumor progression and poor prognosis in esophageal squamous cell carcinoma［J］. Diagn Pathol, 2013, 8: 177. DOI: 10.1186/174615968177. ［14］ Li M, Cui X, Shen Y, et al. ORAOV1 overexpression in esophageal squamous cell carcinoma and esophageal dysplasia: a possible biomarker of progression and poor prognosis in esophageal carcinoma［J］. Hum Pathol, 2015, 46(5): 707715. DOI: 10.1016/j.humpath.2015.01.009. ［15］ Cui XB, Shen YY, Jin TT, et al. SLC39A6: a potential target for diagnosis and therapy of esophageal carcinoma［J］. J Transl Med, 2015, 13: 321. DOI: 10.1186/s129670150681z. ［16］ Chen G, Xu R, Yue B, et al. The expression of podoplanin protein is a diagnostic marker to distinguish the early infiltration of esophageal squamous cell carcinoma［J］. Oncotarget, 2017, 8(12): 1901319020. DOI: 10.18632/oncotarget.14596. ［17］ Shang L, Hao JJ, Zhao XK, et al. ANO1 protein as a potential biomarker for esophageal cancer prognosis and precancerous lesion development prediction［J］. Oncotarget, 2016, 7(17): 2437424382. DOI: 10.18632/oncotarget.8223. ［18］ Yu J, Zheng Y, Han XP, et al. Threegene immunohistochemical panel predicts progression and unfavorable prognosis in esophageal squamous cell carcinoma［J］. Hum Pathol, 2018. pii: S00468177(18)304829. DOI: 10.1016/j.humpath.2018.11.027. ［19］ Zhang H, Li H, Ma Q, et al. Predicting malignant transformation of esophageal squamous cell lesions by combined biomarkers in an endoscopic screening program［J］. World J Gastroenterol, 2016, 22(39): 87708778. DOI: 10.3748/wjg.v22.i39.8770. ［20］ Zhou SL, Yue WB, Fan ZM, et al. Autoantibody detection to tumorassociated antigens of P53, IMP1, P16, cyclin B1, P62, Cmyc, Survivn, and Koc for the screening of highrisk subjects and early detection of esophageal squamous cell carcinoma［J］. Dis Esophagus, 2014, 27(8): 790797. DOI: 10.1111/dote.12145. ［21］ Pritchett NR, Burgert SL, Murphy GA, et al. Cross sectional study of serum selenium concentration and esophageal squamous dysplasia in western Kenya［J］. BMC Cancer, 2017, 17(1): 835. DOI: 10.1186/s1288501738379. ［22］ Abnet CC, Chen W, Dawsey SM, et al. Serum 25(OH)vitamin D concentration and risk of esophageal squamous dysplasia［J］. Cancer Epidemiol Biomarkers Prev, 2007, 16(9): 18891893. DOI: 10.1158/10559965.EPI070461. ［23］ Yu G, Gail MH, Shi J, et al. Association between upper digestive tract microbiota and cancerpredisposing states in the esophagus and stomach［J］. Cancer Epidemiol Biomarkers Prev, 2014, 23(5): 735741. DOI: 10.1158/10559965.EPI130855. ［24］ Chen X, Winckler B, Lu M, et al. Oral microbiota and risk for esophageal squamous cell carcinoma in a highrisk area of China［J］. PLoS One, 2015, 10(12): e0143603. DOI: 10.1371/journal.pone.0143603.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[4]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[5]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291.
[6]	Wan Fang, Yang Gang, Li Rui, Wan Qijing. Expression levels and clinical significance of serum miR-497 and miR-383 in patients with esophageal cancer [J]. Journal of International Oncology, 2024, 51(4): 204-209.
[7]	Gong Yan, Chen Honglei. Research progress on the mechanism of microRNA regulation of cisplatin resistance in ovarian cancer [J]. Journal of International Oncology, 2024, 51(3): 186-190.
[8]	Liu Bohan, Huang Junxing. Research progress of liquid biopsy technology in esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(2): 105-108.
[9]	Gao Xinyu, Li Zhenjiang, Sun Hongfu, Han Dan, Zhao Qian, Liu Chengxin, Huang Wei. Clinical application of MR-guided radiotherapy based on MR-linac in esophageal cancer patients [J]. Journal of International Oncology, 2024, 51(1): 37-42.
[10]	Huang Zhen, Chen Yongshun. Research progress of circulating tumor DNA in the diagnosis and treatment of hepatocellular carcinoma [J]. Journal of International Oncology, 2024, 51(1): 59-64.
[11]	Liu Yang, Jiang Lulu, Guan Kaiwen, Zhou Yueyang, Kang Xiaohong. Role of linc01410 in the occurrence and development of malignant tumors [J]. Journal of International Oncology, 2023, 50(9): 540-543.
[12]	Shandong Medical Association Multidisciplinary Joint Committee on Lung Cancer. Shandong Provincial Medical Association multidisciplinary standardized diagnosis and treatment guidelines for esophageal carcinoma （2023 Edition） [J]. Journal of International Oncology, 2023, 50(7): 385-397.
[13]	Wu Jiali, Zhang Jiahui, Zhang Ping, Xiao Xinyue, Li Rui, Zhang Hongyu. Mechanism of Bcl-2 BH4 selective inhibitor BDA-366 on NK/T cell lymphoma cells [J]. Journal of International Oncology, 2023, 50(7): 413-418.
[14]	Cui Manli, Lu Ning, Zhu Lin, Li Qian, Zhang Mingxin. Analysis of circRNA in esophageal squamous cell carcinoma based on high-throughput sequencing data [J]. Journal of International Oncology, 2023, 50(6): 328-335.
[15]	Zhu Siyu, Wang Xuehong, Li Wenqian, Liu Shu. Level of serum FABP1 and its relationship with Helicobacter pylori infection in patients with gastric cancer [J]. Journal of International Oncology, 2023, 50(6): 336-341.